Foghorn Therapeutics (FHTX) Accumulated Expenses (2019 - 2026)

Foghorn Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 7.28% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 7.28% increase from a year earlier, with the FY2025 full-year figure at $11.4 million, up 33.13% from the prior year.
• Accumulated Expenses retreated to $6.9 million in Q1 2026 per FHTX's latest filing, from $11.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.4 million in Q4 2025 and bottomed at $6.3 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $8.6 million (2025), against an average of $8.6 million.
• Across the five-year window, Accumulated Expenses soared 57.14% in 2022 and slipped 29.06% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $11.0 million in 2022, then dropped by 17.21% to $9.1 million in 2023, then decreased by 6.34% to $8.5 million in 2024, then surged by 33.13% to $11.4 million in 2025, then sank by 39.03% to $6.9 million in 2026.
• Per Business Quant, the three latest FHTX Accumulated Expenses figures stand at $6.9 million (Q1 2026), $11.4 million (Q4 2025), and $9.8 million (Q3 2025).